(Q54903526)

English

M229

cell line

In more languages

default for all languages

No label defined

No description defined

Statements

1 reference

Cellosaurus release 49

14 July 2024

cancer cell line

1 reference

Cellosaurus release 49

14 July 2024

described by source

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

1 reference

Cellosaurus release 49

14 July 2024

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

1 reference

Cellosaurus release 49

14 July 2024

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

1 reference

Cellosaurus release 49

14 July 2024

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

1 reference

Cellosaurus release 49

14 July 2024

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

1 reference

Cellosaurus release 49

14 July 2024

Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

1 reference

Cellosaurus release 49

14 July 2024

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

1 reference

Cellosaurus release 49

14 July 2024

established from medical condition

1 reference

Cellosaurus release 49

14 July 2024

derived from organism type

unknown value

2 references

Cellosaurus release 44

23 January 2023

Cellosaurus release 49

14 July 2024

Identifiers

1 reference

Cellosaurus release 49

14 July 2024

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54903526&oldid=2258402944"